Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163


Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects.

Miao Z, Nucci G, Amin N, Sharma R, Mascitti V, Tugnait M, Vaz AD, Callegari E, Kalgutkar AS.

Drug Metab Dispos. 2013 Feb;41(2):445-56. doi: 10.1124/dmd.112.049551.


Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans.

Vincent SH, Reed JR, Bergman AJ, Elmore CS, Zhu B, Xu S, Ebel D, Larson P, Zeng W, Chen L, Dilzer S, Lasseter K, Gottesdiener K, Wagner JA, Herman GA.

Drug Metab Dispos. 2007 Apr;35(4):533-8.


The absorption, metabolism, and excretion of the novel neuromodulator RWJ-333369 (1,2-ethanediol, [1-2-chlorophenyl]-, 2-carbamate, [S]-) in humans.

Mannens GS, Hendrickx J, Janssen CG, Chien S, Van Hoof B, Verhaeghe T, Kao M, Kelley MF, Goris I, Bockx M, Verreet B, Bialer M, Meuldermans W.

Drug Metab Dispos. 2007 Apr;35(4):554-65.


Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys.

Tan EY, Hartmann G, Chen Q, Pereira A, Bradley S, Doss G, Zhang AS, Ho JZ, Braun MP, Dean DC, Tang W, Kumar S.

Drug Metab Dispos. 2010 Mar;38(3):459-73. doi: 10.1124/dmd.109.028696.


Metabolism and disposition of a potent and selective GABA-Aalpha2/3 receptor agonist in healthy male volunteers.

Polsky-Fisher SL, Vickers S, Cui D, Subramanian R, Arison BH, Agrawal NG, Goel TV, Vessey LK, Murphy MG, Lasseter KC, Simpson RC, Vega JM, Rodrigues AD.

Drug Metab Dispos. 2006 Jun;34(6):1004-11.


Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.

Takusagawa S, van Lier JJ, Suzuki K, Nagata M, Meijer J, Krauwinkel W, Schaddelee M, Sekiguchi M, Miyashita A, Iwatsubo T, van Gelderen M, Usui T.

Drug Metab Dispos. 2012 Apr;40(4):815-24. doi: 10.1124/dmd.111.043588.


Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state.

Waldmeier F, Bruin GJ, Glaenzel U, Hazell K, Sechaud R, Warrington S, Porter JB.

Drug Metab Dispos. 2010 May;38(5):808-16. doi: 10.1124/dmd.109.030833.


Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.

Martin P, Oliver S, Kennedy SJ, Partridge E, Hutchison M, Clarke D, Giles P.

Clin Ther. 2012 Jan;34(1):221-37. doi: 10.1016/j.clinthera.2011.11.011.


Metabolism and disposition of a selective alpha(7) nicotinic acetylcholine receptor agonist in humans.

Shaffer CL, Gunduz M, Scialis RJ, Fang AF.

Drug Metab Dispos. 2007 Jul;35(7):1188-95.


Metabolic disposition of [14C]bazedoxifene in healthy postmenopausal women.

Chandrasekaran A, McKeand WE, Sullivan P, DeMaio W, Stoltz R, Scatina J.

Drug Metab Dispos. 2009 Jun;37(6):1219-25. doi: 10.1124/dmd.108.023861.


Metabolism and pharmacokinetics of indacaterol in humans.

Kagan M, Dain J, Peng L, Reynolds C.

Drug Metab Dispos. 2012 Sep;40(9):1712-22. doi: 10.1124/dmd.112.046151.


Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans.

Christopher LJ, Hong H, Vakkalagadda BJ, Clemens PL, Su H, Roongta V, Allentoff A, Sun H, Heller K, Harbison CT, Iyer RA, Humphreys WG, Wong T, Zhang S.

Drug Metab Dispos. 2010 Nov;38(11):2049-59. doi: 10.1124/dmd.110.034850.


Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies.

Sigafoos JF, Bowers GD, Castellino S, Culp AG, Wagner DS, Reese MJ, Humphreys JE, Hussey EK, O'Connor Semmes RL, Kapur A, Tao W, Dobbins RL, Polli JW.

Drug Metab Dispos. 2012 Nov;40(11):2090-101. doi: 10.1124/dmd.112.047258.


Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects.

Chen N, Wen L, Lau H, Surapaneni S, Kumar G.

Cancer Chemother Pharmacol. 2012 Mar;69(3):789-97. doi: 10.1007/s00280-011-1760-3.


Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs.

Beconi MG, Reed JR, Teffera Y, Xia YQ, Kochansky CJ, Liu DQ, Xu S, Elmore CS, Ciccotto S, Hora DF, Stearns RA, Vincent SH.

Drug Metab Dispos. 2007 Apr;35(4):525-32.


Absorption, metabolism, and excretion of [(14)C]MK-0524, a prostaglandin D(2) receptor antagonist, in humans.

Karanam B, Madeira M, Bradley S, Wenning L, Desai R, Soli E, Schenk D, Jones A, Dean B, Doss G, Garrett G, Crumley T, Nirula A, Lai E.

Drug Metab Dispos. 2007 Jul;35(7):1196-202.

Items per page

Supplemental Content

Support Center